234 related articles for article (PubMed ID: 30651043)
21. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
Saxena V; Panicucci R; Joshi Y; Garad S
J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
[TBL] [Abstract][Full Text] [Related]
22. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.
Chapman K; Chivers S; Gliddon D; Mitchell D; Robinson S; Sangster T; Sparrow S; Spooner N; Wilson A
Drug Discov Today; 2014 May; 19(5):528-32. PubMed ID: 24448068
[TBL] [Abstract][Full Text] [Related]
23. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
24. Drug discovery chemistry: a primer for the non-specialist.
Jordan AM; Roughley SD
Drug Discov Today; 2009 Aug; 14(15-16):731-44. PubMed ID: 19416759
[TBL] [Abstract][Full Text] [Related]
25. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development.
Regan D; Garcia K; Thamm D
ILAR J; 2018 Dec; 59(1):99-110. PubMed ID: 30668709
[TBL] [Abstract][Full Text] [Related]
26. A Short History of the Origins of the European Society of Veterinary Pathology in the Arbeitsgemeinschaft der Veterinärpathologen.
Pospischil A; Hermanns W
Vet Pathol; 2021 Jul; 58(4):655-662. PubMed ID: 34032174
[TBL] [Abstract][Full Text] [Related]
27. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
28. U-BIOPRED: evaluation of the value of a public-private partnership to industry.
Riley JH; Erpenbeck VJ; Matthews JG; Holweg CTJ; Compton C; Seibold W; Higenbottam T; Wagers S; Rowe A; Myles D;
Drug Discov Today; 2018 Sep; 23(9):1622-1634. PubMed ID: 29936248
[TBL] [Abstract][Full Text] [Related]
29. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
30. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.
Tomlinson L; Boone LI; Ramaiah L; Penraat KA; von Beust BR; Ameri M; Poitout-Belissent FM; Weingand K; Workman HC; Aulbach AD; Meyer DJ; Brown DE; MacNeill AL; Bolliger AP; Bounous DI
Vet Clin Pathol; 2013 Sep; 42(3):252-69. PubMed ID: 23889060
[TBL] [Abstract][Full Text] [Related]
31. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
[TBL] [Abstract][Full Text] [Related]
32. Practical Strategies for Navigating Toxicologic Pathology in One's Early Career…and Beyond!
Carreira V; Palanisamy G; Quist E; Nelson K; Fossey S; Zimmerman B; Ramaiah L; Schafer KA
Toxicol Pathol; 2018 Dec; 46(8):1037-1048. PubMed ID: 30352538
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
34. Accelerated drug discovery by rapid candidate drug identification.
Bergström F; Lindmark B
Drug Discov Today; 2019 Jun; 24(6):1237-1241. PubMed ID: 30946980
[TBL] [Abstract][Full Text] [Related]
35. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions.
Everitt JI
Toxicol Pathol; 2015 Jan; 43(1):70-7. PubMed ID: 25351920
[TBL] [Abstract][Full Text] [Related]
36. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
37. Drug discovery management, small is still beautiful: Why a number of companies get it wrong.
Knutsen LJ
Drug Discov Today; 2011 Jun; 16(11-12):476-84. PubMed ID: 21504798
[TBL] [Abstract][Full Text] [Related]
38. Conference Report: High-resolution MS in drug discovery and development: current applications and future perspectives.
Weston DJ; Weidolf L
Bioanalysis; 2012 Mar; 4(5):481-6. PubMed ID: 22409547
[TBL] [Abstract][Full Text] [Related]
39. The Drug Discovery Portal: a resource to enhance drug discovery from academia.
Clark RL; Johnston BF; Mackay SP; Breslin CJ; Robertson MN; Harvey AL
Drug Discov Today; 2010 Aug; 15(15-16):679-83. PubMed ID: 20547242
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
